SHL.DE

50.26

-0.95%↓

ARGX

488.1

+0.16%↑

VIE

29.64

-1%↓

BNR

64.2

-2.1%↓

GLPG

24.94

-1.97%↓

SHL.DE

50.26

-0.95%↓

ARGX

488.1

+0.16%↑

VIE

29.64

-1%↓

BNR

64.2

-2.1%↓

GLPG

24.94

-1.97%↓

SHL.DE

50.26

-0.95%↓

ARGX

488.1

+0.16%↑

VIE

29.64

-1%↓

BNR

64.2

-2.1%↓

GLPG

24.94

-1.97%↓

SHL.DE

50.26

-0.95%↓

ARGX

488.1

+0.16%↑

VIE

29.64

-1%↓

BNR

64.2

-2.1%↓

GLPG

24.94

-1.97%↓

SHL.DE

50.26

-0.95%↓

ARGX

488.1

+0.16%↑

VIE

29.64

-1%↓

BNR

64.2

-2.1%↓

GLPG

24.94

-1.97%↓

Kodu・Aktsiate loetelu・Sanofi SA

Sanofi SA

Suletud

Sektor Tervishoid

104.78 -0.46

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

104.78

Max

105.34

Põhinäitajad
By Trading Economics
Sissetulek	1.1B
Müük	916M 11B
P/E Sektori keskmine	24.91 103.001
Aktsiakasum	1.73
Kasumimarginaal	9.78
EBITDA	-136M 2B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+3.32 upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	25. okt 2024

Turustatistika
By TradingEconomics
Turukapital	131B
Eelmine avamishind	105.24
Eelmine sulgemishind	104.78

Tehniline skoor

By Trading Central

Kindlus

Weak Bearish Evidence

104.9 / 105.78 Toetus ja vastupanu

Sanofi SA Graafik

Seotud uudised

25. juuli 2024, 05:44 UTC

Tulu

Sanofi Raises Guidance After Profit, Sales Beat

24. juuli 2024, 10:24 UTC

Tulu

Spanish Bank Santander Raises 2024 Guidance After Earnings Beat -- Update

24. juuli 2024, 05:22 UTC

Tulu

Santander Raises 2024 Revenue Guidance After Earnings Increase

4. juuli 2024, 06:44 UTC

Omandamised, ülevõtmised, äriostud

Bain, Cinven Explore Joint Bid for Sanofi's Consumer Unit, Bloomberg Reports

27. juuni 2024, 10:54 UTC

Suurimad hinnamuutused turgudel

Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment

15. aug 2024, 08:21 UTC

Market Talk

Tulu

European Banks' Net Interest Income Momentum May Have Stalled -- Market Talk

14. aug 2024, 07:07 UTC

Market Talk

Southern European Banks Have Attractive Net Interest Income Dynamics -- Market Talk

26. juuli 2024, 12:53 UTC

Market Talk

Tulu

European Banks' Earnings Season Had Another Good Start -- Market Talk

25. juuli 2024, 13:20 UTC

Tulu

AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD

25. juuli 2024, 11:46 UTC

Market Talk

Tulu

Sanofi Aims to Boost RSV Drug Supply -- Market Talk

25. juuli 2024, 11:23 UTC

Market Talk

Tulu

Sanofi Results Are Positive -- Market Talk

25. juuli 2024, 05:33 UTC

Tulu

Analysts Saw Sanofi 2Q Sales at EUR10.4B

25. juuli 2024, 05:33 UTC

Tulu

Sanofi 2Q Sales EUR10.745B

25. juuli 2024, 05:30 UTC

Tulu

Sanofi Had Seen 2024 Business Earnings Per Share Decreasing Low Single Digit at Constant Currency

25. juuli 2024, 05:30 UTC

Tulu

Sanofi Now Expects 2024 Business Earnings Per Share to Be Stable at Constant Currency

25. juuli 2024, 05:30 UTC

Tulu

Analysts Saw Sanofi 2Q Business Operating Income at EUR2.69B

25. juuli 2024, 05:30 UTC

Tulu

Sanofi 2Q Net Pft EUR1.11B

25. juuli 2024, 05:30 UTC

Tulu

Sanofi Raises 2024 View

25. juuli 2024, 05:30 UTC

Tulu

Sanofi 2Q Business Operating Income EUR2.81B

24. juuli 2024, 06:53 UTC

Market Talk

Tulu

Santander's Small Beats, Improved Outlook Should Be Well Received -- Market Talk

24. juuli 2024, 04:50 UTC

Tulu

Santander Raises 2024 Rev View

24. juuli 2024, 04:50 UTC

Tulu

Santander Fully-Loaded CET1 Ratio 12.5% at 2Q-End

24. juuli 2024, 04:48 UTC

Tulu

Santander 2Q Net Interest Income Fell 4.2%

24. juuli 2024, 04:48 UTC

Tulu

Santander 2Q Net Interest Income EUR11.47B

24. juuli 2024, 04:48 UTC

Tulu

Santander 2Q Net Pft EUR3.21B

24. juuli 2024, 04:47 UTC

Tulu

Santander 2Q Rev EUR15.67B

9. juuli 2024, 09:05 UTC

Peamised uudised

These Stocks Are Moving the Most Today: Tesla, Corning, BP, Intel, and More -- Barrons.com

3. juuli 2024, 14:18 UTC

Omandamised, ülevõtmised, äriostud

GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines -- Barrons.com

27. juuni 2024, 10:39 UTC

Suurimad hinnamuutused turgudel

Vigil Neuroscience Shares Soar on $40M Sanofi Investment

27. juuni 2024, 06:08 UTC

Omandamised, ülevõtmised, äriostud

Vigil Neuroscience Is a Clinical-Stage Biotechnology Company >VIGL

Võrdlus sarnastega

Hinnamuutus

Sanofi SA Prognoos

Hinnasiht

By TipRanks

3.32% tõus

12 kuu keskmine prognoos

Keskmine 108.4 EUR 3.32%

Kõrge 125 EUR

Madal 85 EUR

Põhineb 12 Wall Streeti analüütiku instrumendi Sanofi SA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi Sanofi SA aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

104.9 / 105.78Toetus ja vastupanu

Bearish events outweigh bullish events.

All events are bullish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Sanofi SA

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.